NextCure, Inc. (NXTC) vs TransCode Therapeutics Inc. (RNAZ)

NextCure, Inc. and TransCode Therapeutics Inc. are both Biotechnology companies. TransCode Therapeutics Inc. is the larger, with a market value of $27.9M against $25.4M — 1.1× the size. Across the 7 metrics below, TransCode Therapeutics Inc. leads on 4 and NextCure, Inc. on 3.

Valuation

Metric NXTC RNAZ Biotechnology median
P/E n/m n/m 7.88
P/S 0.99 n/m 11.47
P/B 2.22 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.15 0.74
EV/Sales 0.49 n/m 10.73
Earnings yield (171.26%) (3,098.82%) (28.84%)
Free cash flow yield (138.87%) (1,398.93%) (23.03%)

Profitability

Metric NXTC RNAZ Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (195.22%) 429.61% (57.72%)
Return on assets (121.60%) (58.12%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NXTC RNAZ Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 17.75% 96.02% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NXTC RNAZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.47 1.97 4.73
Net debt to EBITDA 0.75 0.64 0.96

Dividend

Metric NXTC RNAZ Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NXTC RNAZ Biotechnology median
Market cap 25.36m 27.94m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack